Prospective evaluation of cardiac safety in breast cancer patients after adjuvant treatment with epirubicin, cyclophosphamide, doxetaxel and with or without trastuzumab: A single…

Anticancer drugs can cause cardiotoxicity. Chemotherapy with antracyclines is associated with electrocardiographic alterations including prolongation of the corrected QT (QTc) interval with the risk of life threatening arrhythmias. Among the new targeted therapies QTc aberrations were reported upon treatment with anti HER2/neu agents. The combination of the antracycline epirubicin and monoclonal antibody trastuzumab against HER2/neu positive breast cancers might potentiate this cardiotoxic effect. In this observational study we assessed the cardiac safety in 19 adjuvant treated breast cancer patients. All 9 HER2…